M&A Deal Summary |
|
---|---|
Date | 2009-03-29 |
Target | CuraGen |
Sector | Life Science |
Buyer(s) | Celldex Therapeutics |
Deal Type | Add-on Acquisition |
Deal Value | 95M USD |
Advisor(s) | Piper Jaffray Companies (Financial) Wilmer Cutler Pickering Hale and Dorr (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1983 |
Sector | Life Science |
Employees | 148 |
Revenue | 7M USD (2023) |
Celldex Therapeutics is an integrated bio pharmaceutical company that applies its comprehensive precision targeted immunotherapy platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex Therapeutics was founded in 1983 and is based in Hampton, New Jersey.
DEAL STATS | # |
---|---|
Overall | 2 of 3 |
Sector (Life Science) | 2 of 3 |
Type (Add-on Acquisition) | 2 of 3 |
State (Connecticut) | 1 of 2 |
Country (United States) | 2 of 3 |
Year (2009) | 1 of 1 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2005-10-12 |
Alteris Therapeutics
Philadelphia, Pennsylvania, United States Alteris Therapeutics, Inc. engages in the discovery and development of therapeutics and vaccines based on alternative gene splice forms for the treatment of cancer. I |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-11-01 |
Kolltan Pharmaceuticals
New Haven, Connecticut, United States Kolltan Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs). |
Buy | $63M |